Switzerland · Delayed Price · Currency is CHF Newron Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
FDA feedback prompted broader cardiac review and proposed screening safeguards for ENIGMA-TRS 2, while non-U.S. enrollment continues. ENIGMA-TRS 1 had 514 patients randomized, with 12-week results expected in Q1 2027; funding extends through most of 2027.
-
A novel glutamate modulator for schizophrenia is advancing through two pivotal phase III trials, targeting a large unmet need with strong efficacy, safety, and IP protection. Key results are expected in 2027, with significant commercial and regulatory momentum.
-
A novel add-on therapy for treatment-resistant schizophrenia is advancing through three pivotal global studies, showing sustained efficacy and a unique mechanism targeting hippocampal hyperexcitability. Regulatory submission is expected within 12–15 months, with strong physician interest and no direct competition in its segment.
Fiscal Year 2025
-
Achieved major milestones with pivotal phase III studies for evenamide, strong financial position, and new IP protection. Results expected by end of 2026 will support NDA submission, with additional funding and NASDAQ uplisting preparations underway.
Fiscal Year 2024
-
Record revenues and first-ever net profit achieved, driven by licensing deals and strong clinical results for evenamide. Major partnerships, robust financial position, and Nasdaq uplisting plans set the stage for pivotal phase III results in 2026.
-
Evenamide, a novel glutamate modulator, is advancing to a pivotal phase III trial as an add-on for treatment-resistant schizophrenia, with strong regulatory alignment and robust prior efficacy and safety data. The company is pursuing strategic partnerships and expects significant value creation upon trial success.